Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children’s Oncology Group Report

Author:

Marina Neyssa1,Granowetter Linda2,Grier Holcombe E.3,Womer Richard B.4,Randall R. Lor5,Marcus Karen J.6,McIlvaine Elizabeth78,Krailo Mark78

Affiliation:

1. Department of Pediatrics, Stanford University and Lucile Packard Children’s Hospital, 1000 Welch Road, Suite 300, Palo Alto, CA 94304-1812, USA

2. Department of Pediatrics, New York University, Langone Medical Center, New York, NY 10016, USA

3. Pediatric Hematology-Oncology, Dana Farber & Boston Children’s Hospital, 44 Binney Street, Boston, MA 02115, USA

4. Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA

5. Sarcoma Services, Huntsman Cancer Institute and Primary Children’s Medical Center Department of Orthopaedics, University of Utah, Salt Lake City, UT 84112, USA

6. Department of Radiation Oncology, Boston Children’s Hospital/Dana Farber Cancer Institute Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

7. Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90027, USA

8. Children’s Oncology Group Statistics, Monrovia, CA 91016, USA

Abstract

Purpose. To associate baseline patient characteristics and relapse across consecutive COG studies.Methods. We analyzed risk factors for LESFT patients in three randomized COG trials. We evaluated age at enrollment, primary site, gender, tumor size, and treatment (as randomized). We estimated event-free survival (EFS, Kaplan-Meier) and compared risk across groups (log-rank test). Characteristics were assessed by proportional hazards regression with the characteristic of interest as the only component. Confidence intervals (CI) for RR were derived. Factors related to outcome at level 0.05 were included in a multivariate regression model.Results. Between 12/1988 and 8/2005, 1444 patients were enrolled and data current to 2001, 2004, or 2008 were used. Patients were with a median age of 12 years (0–45), 55% male and 88% Caucasian. The 5-year EFS was 68.3% ± 1.3%. In univariate analysis age, treatment, and tumor location were identified for inclusion in the multivariate model, and all remained significant (p< 0.01). Since tumor size was not collected in the last study, the other two were reanalyzed. This model identified age, treatment, tumor location, and tumor size as significant predictors.Conclusion. Age > 18 years, pelvic tumor, size > 8 cms, and chemotherapy without ifosfamide/etoposide significantly predict worse outcome. AEWS0031 isNCT00006734, INT0091 and INT0054 designed before 1993 (unregistered).

Funder

Daniel P. Sullivan Fund

Publisher

Hindawi Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3